Fulcrum Therapeutics announces PIONEER trial data presentation for pociredir in sickle cell disease at ASH on December 6-7, 2025.
Quiver AI Summary
Fulcrum Therapeutics, Inc. has announced that new data from the Phase 1b PIONEER trial of pociredir, a treatment for sickle cell disease (SCD), will be presented at the 67th American Society of Hematology (ASH) Annual Meeting. The trial results will include findings from the 12 mg dose cohort and initial data from the 20 mg cohort, highlighting pociredir's potential as a disease-modifying therapy. The presentation will take place on December 6, along with preclinical data on calmodulin pathway modulators for treating bone marrow failure syndromes. Fulcrum will also host a live investor event on December 7, discussing these results in detail. Pociredir is designed to increase fetal hemoglobin expression and is being developed for SCD, having received FDA Fast Track and Orphan Drug designations.
Potential Positives
- Fulcrum Therapeutics will present new clinical data from the Phase 1b PIONEER trial of pociredir at a prominent hematology conference, highlighting the potential for pociredir as a disease-modifying therapy for sickle cell disease.
- The pociredir trial data has been selected for inclusion in the ASH Poster Walk, showcasing it among cutting-edge emerging science in hematology.
- Fulcrum will host a live webcast investor event featuring company leadership and medical experts, enhancing engagement and visibility with stakeholders.
- Pociredir has received FDA Fast Track designation and Orphan Drug Designation, underscoring its significance and the potential for expedited development in treating sickle cell disease.
Potential Negatives
- The announcement of clinical data may indicate ongoing uncertainty about the trial's overall success and the efficacy of pociredir, as it relies on preliminary results and further characterization.
- There is a risk that the investor event may not generate anticipated interest or confidence from investors if results do not meet expectations.
- The mention of treatment-related adverse events not being reported could imply a heightened scrutiny on safety as the trial progresses, raising concerns about long-term use and side effects.
FAQ
What is the focus of Fulcrum Therapeutics?
Fulcrum Therapeutics focuses on developing small molecules for genetically defined rare diseases, particularly those with high unmet medical needs.
What data will be presented at the ASH Annual Meeting?
Fulcrum will present data from the Phase 1b PIONEER trial of pociredir in sickle cell disease, including findings from 12 mg and 20 mg cohorts.
When is the investor event scheduled?
The investor event will be held on Sunday, December 7, 2025, at 7:00 a.m. ET in Orlando and available via webcast.
What clinical significance does pociredir have for sickle cell disease?
Pociredir is being developed as a potential disease-modifying therapy that increases fetal hemoglobin levels in patients with sickle cell disease.
How can I access the presented posters after the conference?
Posters will be available on Fulcrum's Publications & Presentations page after congress publication at www.fulcrumtx.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FULC Insider Trading Activity
$FULC insiders have traded $FULC stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $FULC stock by insiders over the last 6 months:
- GREG TOURANGEAU (Principal Accounting Officer) sold 498 shares for an estimated $2,519
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$FULC Hedge Fund Activity
We have seen 57 institutional investors add shares of $FULC stock to their portfolio, and 63 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,589,000 shares (+53.0%) to their portfolio in Q2 2025, for an estimated $10,932,320
- BALYASNY ASSET MANAGEMENT L.P. added 1,338,214 shares (+inf%) to their portfolio in Q2 2025, for an estimated $9,206,912
- GOLDMAN SACHS GROUP INC added 740,936 shares (+184.0%) to their portfolio in Q2 2025, for an estimated $5,097,639
- D. E. SHAW & CO., INC. added 596,050 shares (+102.7%) to their portfolio in Q2 2025, for an estimated $4,100,824
- NANTAHALA CAPITAL MANAGEMENT, LLC removed 534,394 shares (-11.1%) from their portfolio in Q2 2025, for an estimated $3,676,630
- POINT72 ASSET MANAGEMENT, L.P. added 498,219 shares (+inf%) to their portfolio in Q2 2025, for an estimated $3,427,746
- ADAR1 CAPITAL MANAGEMENT, LLC removed 437,183 shares (-89.1%) from their portfolio in Q2 2025, for an estimated $3,007,819
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$FULC Analyst Ratings
Wall Street analysts have issued reports on $FULC in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 10/30/2025
- HC Wainwright & Co. issued a "Buy" rating on 07/29/2025
- Leerink Partners issued a "Outperform" rating on 05/23/2025
- Cantor Fitzgerald issued a "Overweight" rating on 05/15/2025
To track analyst ratings and price targets for $FULC, check out Quiver Quantitative's $FULC forecast page.
$FULC Price Targets
Multiple analysts have issued price targets for $FULC recently. We have seen 6 analysts offer price targets for $FULC in the last 6 months, with a median target of $12.0.
Here are some recent targets:
- Edward Tenthoff from Piper Sandler set a target price of $16.0 on 10/30/2025
- Luca Issi from RBC Capital set a target price of $7.0 on 10/30/2025
- Andrew S. Fein from HC Wainwright & Co. set a target price of $12.0 on 10/20/2025
- Joseph Schwartz from Leerink Partners set a target price of $12.0 on 05/23/2025
- Kristen Kluska from Cantor Fitzgerald set a target price of $10.0 on 05/15/2025
Full Release
― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ―
― Live and Webcast Investor Event with Fulcrum Leadership and Medical Experts will be Hosted Onsite on Sunday, December 7 ―
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that new data from the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) will be presented at the 67 th American Society of Hematology (ASH) Annual Meeting. Additionally, Fulcrum will present preclinical data highlighting its calmodulin pathway modulator program for the potential treatment of bone marrow failure syndromes.
“We are looking forward to presenting new clinical data from the PIONEER trial at ASH, including full data from the 12 mg dose cohort and initial data from the 20 mg dose cohort,” said Alex C. Sapir, Fulcrum’s President and Chief Executive Officer. “These data will further characterize pociredir’s potential as a disease-modifying therapy for sickle cell disease, and we look forward to discussing the results in greater detail during our investor event at ASH.”
Presentation details are as follows:
Title
: Pociredir, a novel oral once-daily fetal hemoglobin inducer: Results from the Phase 1b PIONEER study in adult participants with severe sickle cell disease and hydroxyurea intolerance or unresponsiveness
Format
: Poster
ID
: 1157
First Author
: Dr. Sheinei Alan, UVA School of Medicine
Presentation Session Date and Time
: Saturday, December 6, 2025, between 5:30 – 7:30 PM ET
Title
: First-in-class small molecule calmodulin pathway modulators attenuate excess p53 activity and correct erythropoietic defects in models of diamond-blackfan anemia (DBA)
Format
: Poster
ID
: 1441
First Author
: Avik Choudhuri, Senior Scientist, Hematology, Fulcrum
Presentation Session Date and Time
: Saturday, December 6, 2025, between 5:30 – 7:30 PM ET
In addition, the pociredir poster has been selected for inclusion in the Poster Walk on Novel and Emerging Therapeutics in Erythrocyte and Iron Disorders Hosted by Blood Red Cells & Iron, which will take place on Sunday, December 7, from 11:15 a.m. to 12:15 p.m. ET. The ASH Poster Walks highlight cutting-edge emerging science in hematology presented in the poster sessions during the meeting.
Following congress publication, the posters will be available on the Publications & Presentations Page of Fulcrum’s website at https://www.fulcrumtx.com/publications-presentations .
Investor Event at ASH 2025
Fulcrum will host a live and webcast investor event featuring company leadership and medical experts on Sunday, December 7, 2025, at 7:00 a.m. ET in Orlando. A live webcast will be accessible on the Investor Relations section of Fulcrum’s website (
www.fulcrumtx.com
) under Events and Presentations, with a recording available following the event. Further details on specific location to follow.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of HbF for the treatment of SCD. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit
www.fulcrumtx.com
and follow us on X (@FulcrumTx) and LinkedIn.
About Pociredir
Pociredir is an investigational oral small-molecule inhibitor of EED that was discovered using Fulcrum’s proprietary discovery technology. Inhibition of EED leads to potent downregulation of key fetal globin repressors, including BCL11A, thereby causing an increase in HbF. Pociredir is being developed for the treatment of SCD. Initial data in SCD in the PIONEER Phase 1b clinical trial showed proof-of-concept and achieved absolute levels of HbF increases associated with potential overall patient benefit. Through the completion of the 12 mg dose cohort, pociredir was demonstrated to be generally well-tolerated in people with SCD with up to three months of exposure, with no treatment-related SAEs reported. Pociredir has been granted FDA Fast Track designation and Orphan Drug Designation for the treatment of SCD. To learn more about clinical trials of pociredir please visit
ClinicalTrials.gov
.
About Sickle Cell Disease
SCD is a genetic disorder of the red blood cells caused by a mutation in the HBB gene. This gene encodes a protein that is a key component of hemoglobin, a protein complex whose function is to transport oxygen in the body. The result of the mutation is less efficient oxygen transport and the formation of red blood cells that have a sickle shape. These sickle shaped cells are much less flexible than healthy cells and can block blood vessels or rupture cells. People with SCD typically suffer from serious clinical consequences, which may include anemia, pain, infections, stroke, heart disease, pulmonary hypertension, kidney failure, liver disease, and reduced life expectancy.
Contact:
Kevin Gardner
LifeSci Advisors, LLC
[email protected]
617-283-2856
